PFIZER INC
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
PFE$29.36+0.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Total Revenues by Geography
| The following presents worldwide Total revenues by geography: | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year Ended December 31, · % Change | ||||||||||||||||||
| Worldwide · U.S. · International · Worldwide · U.S. · International | ||||||||||||||||||
| (MILLIONS) · 2024 · 2023 · 2022 · 2024 · 2023 · 2022 · 2024 · 2023 · 2022 · 24/23 · 23/22 · 24/23 · 23/22 · 24/23 · 23/22 | ||||||||||||||||||
| Operating segments: | ||||||||||||||||||
| Biopharma | $62,400 | $58,237 | $99,826 | $38,332 | $27,749 | $42,920 | $24,068 | $30,488 | $56,905 | 7 | (42) | 38 | (35) | (21) | (46) | |||
| Pfizer CentreOne | 1,146 | 1,272 | 1,342 | 278 | 352 | 390 | 868 | 920 | 952 | (10) | (5) | (21) | (10) | (6) | (3) | |||
| Pfizer Ignite | 82 | 44 | 7 | 82 | 44 | 7 | — | — | — | 85 | * | 85 | * | — | — | |||
| Total revenues | $63,627 | $59,553 | $101,175 | $38,691 | $28,145 | $43,317 | $24,936 | $31,408 | $57,858 | 7 | (41) | 37 | (35) | (21) | (46) | |||
| The following provides an analysis of the worldwide change in Total revenues by geographic areas from 2023 to 2024: | |||
|---|---|---|---|
| (MILLIONS) | Worldwide | U.S. | International |
| Operational growth/(decline): | |||
| Worldwide growth from Paxlovid | $4,452 | $5,905 | $(1,453) |
| Increase in revenues from legacy Seagen, which was acquired in December 2023 | 3,223 | 3,071 | 153 |
| Worldwide growth from the Vyndaqel family, Eliquis, Xtandi and Nurtec ODT/Vydura, partially offset by declines from Xeljanz, Ibrance, Abrysvo, Inlyta and the Prevnar family | 2,403 | 1,770 | 633 |
| Worldwide declines from Comirnaty | (5,907) | (400) | (5,507) |
| Decline in oncology biosimilars, largely due to lower net price in the U.S. | (362) | (338) | (24) |
| Other operational factors, net | 614 | 538 | 76 |
| Operational growth/(decline), net | 4,423 | 10,546 | (6,123) |
| Unfavorable impact of foreign exchange | (349) | — | (349) |
| Total revenues increase/(decrease) | $4,074 | $10,546 | $(6,472) |
2023 v.2022
| The following provides an analysis of the worldwide change in Total revenues by geographic areas from 2022 to 2023: | |||
|---|---|---|---|
| (MILLIONS) | Worldwide | U.S. | International |
| Operational growth/(decline): | |||
| Worldwide declines from Comirnaty | $(26,427) | $(6,374) | $(20,053) |
| Worldwide declines from Paxlovid | (17,506) | (11,803) | (5,703) |
| Worldwide growth from the Vyndaqel family, Eliquis, the Prevnar family and Inlyta, partially offset by worldwide declines from Ibrance and Xeljanz | 1,079 | 1,081 | (2) |
| Increase in revenues from Nurtec ODT/Vydura and Oxbryta, which were acquired in the fourth quarter of 2022 | 972 | 949 | 23 |
| Revenues from Abrysvo, primarily driven by launch of the older adult indication in the U.S. in July 2023 | 890 | 888 | 2 |
| Revenues from legacy Seagen products subsequent to the acquisition on December 14, 2023 | 132 | 132 | — |
| Other operational factors, net | 260 | (45) | 305 |
| Operational growth/(decline), net | (40,600) | (15,172) | (25,428) |
| Unfavorable impact of foreign exchange | (1,022) | — | (1,022) |
| Total revenues increase/(decrease) | $(41,621) | $(15,172) | $(26,450) |
See the Total Revenues––Selected Product Discussion section within MD&A for additional analysis and Note 17C.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.